Qiagen’s acquisition of Genaco Biomedical this week for $22 million in cash will add to the company’s molecular diagnostic offering, whose cornerstone comprises last year’s acquisitions of Artus and Shenzhen PG Biotech.
Privately held Genaco provides Qiagen with a PCR-based multiplexing technology and a handful of assays that the firm plans to pair with the quantitative molecular diagnostic products it gained through its earlier acquisitions.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.